Patent expirations for blockbuster antipsychotic meds could save billions

Medicaid costs for antipsychotics approaching to diminution as branded antipsychotics come off patent

Medicaid is approaching to save billions of dollars a year as patents for several blockbuster antipsychotic drugs end and use of general versions of these drugs increases, according to a new investigate by researchers during a University of Maryland School of Medicine. These assets might yield service from a high costs of these drugs and concede policymakers to lift restrictions on patients’ access, a researchers argue.

The investigate foresee that annual Medicaid payments for antipsychotic medicines will diminution by scarcely $1.8 billion (or scarcely 50 percent) by 2016 and by $2.8 billion (or 76 percent) by 2019. The forecasting models were grown by a authors, Eric Slade, PhD, an associate highbrow in a Department of Psychiatry and Linda Simoni-Wastila, BSPharm, MSPH, PhD, a highbrow during a University of Maryland School of Pharmacy. The study, a initial to demeanour during these probable cost savings, was published in a Jul emanate of a biography Psychiatric Services.

The researchers likely changes in altogether Medicaid spending for antipsychotics between 2011 and 2019. In 2011, Medicaid spent some-more than $3.6 billion on second-generation antipsychotics. Five branded drugs — aripiprazole, quetiapine, olanzapine, ziprasidone, and paliperidone